The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISLB 2021 | Comprehensive genomic profiling
Umberto Malapelle, PhD, University of Naples Federico II, Naples, Italy, outlines the advantages of comprehensive genomic profiling (a combination of next generation sequencing and liquid biopsy). This technique is effective for detecting a range of mutations and gene alterations at the same time, which allows for faster diagnosis for patients. This interview took place at the International Society of Liquid Biopsy (ISLB) 2021 Virtual Meeting.
Disclosures
Speaker’s bureau for Boehringer Ingelheim, AstraZeneca, Roche, MSD, Amgen, Merck, BMS, Thermofisher, Biocartis.
Advisory role for Boehringer Ingelheim, MSD, Amgen, Merck, BMS, Diaceutics, Roche, Eli Lilly, Thermofisher, Janssen.
